Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer
NCT07797816Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, sintilimab in biliary tract cancer (BTC), sponsored by Nanjing Drum-Tower Hospital. Started Jan 2026; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabsintilimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07797816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07797816.